[go: up one dir, main page]

WO2009086952A3 - Compositions de traitement de maladies articulaires dégénératives - Google Patents

Compositions de traitement de maladies articulaires dégénératives Download PDF

Info

Publication number
WO2009086952A3
WO2009086952A3 PCT/EP2008/062287 EP2008062287W WO2009086952A3 WO 2009086952 A3 WO2009086952 A3 WO 2009086952A3 EP 2008062287 W EP2008062287 W EP 2008062287W WO 2009086952 A3 WO2009086952 A3 WO 2009086952A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
diseases
articular diseases
degenerative articular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/062287
Other languages
English (en)
Other versions
WO2009086952A2 (fr
Inventor
Juan Carlos RODRÍGUEZ CIMADEVILLA
Cecilia Lorena Sgarlata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROJECH SCIENCE TO TECHNOLOGY SL
Original Assignee
PROJECH SCIENCE TO TECHNOLOGY SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROJECH SCIENCE TO TECHNOLOGY SL filed Critical PROJECH SCIENCE TO TECHNOLOGY SL
Publication of WO2009086952A2 publication Critical patent/WO2009086952A2/fr
Publication of WO2009086952A3 publication Critical patent/WO2009086952A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur les utilisations thérapeutiques d'inhibiteurs de la N-acétylglucosamine transférase à O lié dans le traitement de maladies qui mettent en jeu une différenciation cellulaire terminale. En particulier, la présente invention porte sur l'utilisation desdits inhibiteurs pour le traitement de maladies articulaires, notamment pour le traitement de maladies articulaires du cartilage.
PCT/EP2008/062287 2008-01-07 2008-09-16 Compositions de traitement de maladies articulaires dégénératives Ceased WO2009086952A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US999308P 2008-01-07 2008-01-07
US61/009,993 2008-01-07
US6266808P 2008-01-29 2008-01-29
US61/062,668 2008-01-29

Publications (2)

Publication Number Publication Date
WO2009086952A2 WO2009086952A2 (fr) 2009-07-16
WO2009086952A3 true WO2009086952A3 (fr) 2010-04-01

Family

ID=40120099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/062287 Ceased WO2009086952A2 (fr) 2008-01-07 2008-09-16 Compositions de traitement de maladies articulaires dégénératives

Country Status (1)

Country Link
WO (1) WO2009086952A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156676A1 (fr) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Procédés et compositions de détection et de modulation de o-glycosylation
WO2010141074A2 (fr) 2009-06-01 2010-12-09 President And Fellows Of Harvard College Inhibiteurs de la o-glcnac transférase et leurs utilisations
US9573911B2 (en) 2011-07-06 2017-02-21 President And Fellows Of Harvard College Diphosphate mimetics and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003986A1 (fr) * 1981-05-21 1982-11-25 Alfred Jenkinson Composition medicinale
WO1998044123A2 (fr) * 1997-03-31 1998-10-08 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services GlcNAc-TRANSFERASE A LIAISON O (OGT): CLONAGE, EXPRESSION MOLECULAIRE, ET PROCEDES CONCERNANT SON UTILISATION
WO2001058958A1 (fr) * 2000-02-09 2001-08-16 Glaxo Group Limited Proteines de zone superficielle liees a un anticorps et leurs utilisations dans le cadre de procedes de filtrage et de diagnostic
WO2004013326A1 (fr) * 2002-08-05 2004-02-12 Asahi Kasei Pharma Corporation Gene inhibant la differentiation du cartilage
WO2005060977A1 (fr) * 2003-12-22 2005-07-07 Btg International Limited Inhibiteurs de la glcnac-t de structure noyau 2
WO2006114661A1 (fr) * 2005-04-26 2006-11-02 Dwek Raymond A Analyse de glycane a haut rendement pour diagnostiquer et surveiller l'arthrite rhumatoide et d'autres maladies auto-immunes
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
US7256171B1 (en) * 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003986A1 (fr) * 1981-05-21 1982-11-25 Alfred Jenkinson Composition medicinale
WO1998044123A2 (fr) * 1997-03-31 1998-10-08 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services GlcNAc-TRANSFERASE A LIAISON O (OGT): CLONAGE, EXPRESSION MOLECULAIRE, ET PROCEDES CONCERNANT SON UTILISATION
US7256171B1 (en) * 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
WO2001058958A1 (fr) * 2000-02-09 2001-08-16 Glaxo Group Limited Proteines de zone superficielle liees a un anticorps et leurs utilisations dans le cadre de procedes de filtrage et de diagnostic
WO2004013326A1 (fr) * 2002-08-05 2004-02-12 Asahi Kasei Pharma Corporation Gene inhibant la differentiation du cartilage
WO2005060977A1 (fr) * 2003-12-22 2005-07-07 Btg International Limited Inhibiteurs de la glcnac-t de structure noyau 2
WO2006114661A1 (fr) * 2005-04-26 2006-11-02 Dwek Raymond A Analyse de glycane a haut rendement pour diagnostiquer et surveiller l'arthrite rhumatoide et d'autres maladies auto-immunes
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARSONS S ET AL: "Expression of a developmentally regulated epitope on fibronectins from the synovial fluid of patients with rheumatic disease", JOURNAL OF RHEUMATOLOGY, vol. 21, no. 10, 1 October 1994 (1994-10-01), pages 1888 - 1891, XP008118484 *
OTA T & KATSUKI I: "Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis", JOURNAL OF RHEUMATOLOGY, vol. 25, no. 12, 1 December 1998 (1998-12-01), pages 2315 - 2318, XP008118485 *
VOLIN M ET AL: "Human rheumatoid arthritic synovial tissue express mucin 3 and mucin 5AC", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), pages A689 - A690, XP008118486 *

Also Published As

Publication number Publication date
WO2009086952A2 (fr) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2010111406A3 (fr) Composés et leurs utilisations thérapeutiques
CA2871471C (fr) Inhibiteurs d'adn pk
WO2008064018A8 (fr) Thiénopyrimidinones destinées au traitement de troubles inflammatoires et de cancers
WO2010115491A3 (fr) Dérivés de pipéridine et de pyrazine comme inhibiteurs de l'autotaxine
EP2330894B8 (fr) Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
SI2021078T1 (sl) Sulfatirana hialuronska kislina za zdravljenje degenerativnega osteoartritisa
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2010079431A3 (fr) Composés pour la prévention et le traitement de maladies cardiovasculaires
WO2010068292A8 (fr) Dérivés d'azaindole en tant qu'inhibiteurs de kinases
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
WO2011080568A8 (fr) Nouveaux composés de pyrimidine en tant qu'inhibiteurs de mtor et p13k
MX2012004780A (es) Inhibidores de akt.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
WO2007138282A3 (fr) Nouveaux composés
WO2010150211A3 (fr) Utilisation de dérivés d'indoles dans le traitement du cancer
WO2009104021A3 (fr) Nouveaux polymorphes et procédés de préparation
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
PL2445510T3 (pl) Kompozycja do leczenia zwyrodnieniowych chorób stawów
PL2445472T3 (pl) Kompozycja do zastosowań kosmetycznych, farmaceutycznych lub dietetycznych
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08870440

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08870440

Country of ref document: EP

Kind code of ref document: A2